Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

934 - Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: a real-world prospective study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Masato Takahashi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

M. Takahashi1, K. Inoue2, H. Mukai3, T. Yamanaka4, C. Egawa5, Y. Sakata6, H. Ikezawa7, T. Matsuoka6, J. Tsurutani8

Author affiliations

  • 1 Breast Surgery, National Hospital Organization Hokkaido Cancer Center, 003-0804 - Sapporo/JP
  • 2 Breast Oncology, Saitama Cancer Center, 362-0806 - Kita-adachi Ina/JP
  • 3 Breast And Medical Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 4 Breast And Endocrine Surgery, Kanagawa Cancer Center, Yokohama/JP
  • 5 Breast Surgery, Kansai Rosai Hospital, Amagasaki/JP
  • 6 Oncology Medical, Eisai Co., Ltd., 112-8088 - Tokyo/JP
  • 7 Clinical Data Science, Eisai Co., Ltd., Tokyo/JP
  • 8 Medical Oncology, Kindai University Faculty of Medicine, 577-8502 - Osaka/JP
More

Resources

Abstract 934

Background

A global phase III study confirmed the effect of eribulin mesylate (ERI) as third- or later-line chemotherapy on overall survival (OS) for advanced or metastatic breast cancer. Meanwhile, in Japan, ERI can be used as first- or second-line. However, limited reports can be found on time to treatment failure (TTF) and/or OS for ERI as first- or second-line therapy comparing to late-line therapy in clinical practice.

Methods

We conducted a prospective study in patients with inoperable or recurrent HER2-negative breast cancer starting in September, 2014. We enrolled a similar number of patients receiving ERI as first- or second-line therapy and those receiving ERI as third- or later-line therapy, and with follow-up planned for up to two years (ClinicalTrials.gov: NCT02371174). The data collected by November 2017 was analyzed. TTF and OS were estimated using the Kaplan–Meier method. Multivariate Cox regression was used to identify the factors influencing TTF and OS.

Results

We analyzed 634 patients. The mean age (± standard deviation) was 59.6 years (± 11.0), and 157 patients (24.8%) had triple-negative breast cancer. Of these patients, 319 received ERI as first- or second-line therapy and 315 as third- or later-line therapy. The median TTF (95% confidence interval [CI]) was 135 (121–164) and 119 (106–128) days, and the median OS (95% CI) was 555 (475–628) and 383 (342–459) days for first- or second-line- and third- or later-line therapy, respectively. A history of radiation therapy, complication of diabetes, liver metastasis, ECOG performance status, blood hemoglobin and aspartate aminotransferase levels at baseline, triple-negative breast cancer, and development of peripheral neuropathy after ERI treatment were significant factors influencing both TTF and OS.

Conclusions

Our real-world study showed patients with first- or second-line therapy of ERI have longer OS and TTF than those in third- or later-line therapy. These results suggested that patients with first- or second-line therapy of ERI have the potential for similar or more favorable outcomes from the ERI treatment compared with patients with third- or later-line therapy of ERI.

Clinical trial identification

NCT02371174, First release November 21, 2014.

Legal entity responsible for the study

Eisai Co., Ltd.

Funding

Eisai Co., Ltd.

Editorial Acknowledgement

Disclosure

M. Takahashi: Honorarium: Eisai, AstraZeneca, Pfizer. K. Inoue: Research funding (institutional): Eisai, Parexel, Puma Biotechnology, MSD, Novartis, GSK, Pfizer, Chugai Pharmaceutical, Daiichi Sankyo. Y. Sakata, H. Ikezawa, T. Matsuoka: Employee: Eisai Co. J. Tsurutani: Adviser: Eisai Co., Ltd. and Asahi Kasei Corporation; Honoraria: Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Roche Diagnostics K.K., Novartis Pharma, AstraZeneca K.K. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.